|Bid||70.40 x 13300|
|Ask||70.41 x 5400|
|Day's Range||70.11 - 70.75|
|52 Week Range||55.06 - 75.04|
|PE Ratio (TTM)||18.26|
|Earnings Date||Oct 26, 2017 - Oct 30, 2017|
|Dividend & Yield||2.56 (3.61%)|
|1y Target Est||75.56|
AbbVie (ABBV) recorded a 12.0% rise in net revenue for 2016, mainly driven by Humira and Imbruvica.
On the hunt for income? Here's why our team of healthcare experts thinks you should check out AbbVie, Medtronic, and ResMed.
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives AbbVie, Inc. a score of 84. Our analysis is based on comparing AbbVie, Inc. with the following peers – Amgen Inc., Pfizer Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Inc., Biogen Inc., GlaxoSmithKline plc Sponsored ADR, Astrazeneca PLC Sponsored ADR and Neurocrine Biosciences, Inc. ... Read more (Read more...)